Magrolimab MedChemExpress (MCE)

Product Name	Magrolimab
Synonyms	Magrolimab
CAS	2169232-81-7
EINECS
Chemical Formula
Molecular Weight
inchi
Package	1 mg;5 mg;10 mg
Price	Email to quote
Descriptions	Magrolimab Magrolimab MedChemExpress (MCE) HY-P99029 2169232-81-7 Hu5F9-G4 99.92% Please store the product under the recommended conditions in the Certificate of Analysis. Shipping with dry ice. Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer. Magrolimab (10 μg/mL, 24 h) can promote the phagocytic activity of tumor associated macrophages towards ovarian or breast tumor cells[3]. Magrolimab (12-100 μg Descriptions Magrolimab Magrolimab MedChemExpress (MCE) HY-P99029 2169232-81-7 Hu5F9-G4 99.92% Please store the product under the recommended conditions in the Certificate of Analysis. Shipping with dry ice. Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer. Magrolimab (10 μg/mL, 24 h) can promote the phagocytic activity of tumor associated macrophages towards ovarian or breast tumor cells[3]. Magrolimab (12-100 μg once daily 10 days i.p.) exhibits anti-tumor activity in mice with Ewing's sarcoma[1]. Magrolimab (250 μg once every two days 7 weeks i.p.) combined with trastuzumab (HY-P9907) can eliminate HER2 positive breast cancer cells in breast cancer mice and overcome the tolerance of trastuzumab[2]. Humanized Human IgG4 kappa Human IgG4 (S228P) kappa, Isotype Control \| \| \| \| \| \| \| \| \| \| [1]. Luo W, et al. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma. Front Immunol. 2023 Oct 6 14:1277987. [Content Brief] [2]. Upton R, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A. 2021 Jul 20 118(29):e2026849118. [Content Brief] [3]. Liu Y, et al. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors. Life Sci. 2023 Aug 1 326:121790. [Content Brief]
Supplier Website	https://www.medchemexpress.com/magrolimab.html
Last Update	2025-05-21 16:50:25

MedChemExpress (MCE) also provides

Depatuxizumab

Category: Inhibitory Antibodies
CAS: 1471999-69-5
Last Update: 2025-05-21 16:50:25

Raxibacumab

Category: Inhibitory Antibodies
CAS: 565451-13-0
Last Update: 2025-05-21 16:50:25

Crizanlizumab

Category: Inhibitory Antibodies
CAS: 1690318-25-2
Last Update: 2025-05-21 16:50:25

Sofituzumab vedotin

Category: Inhibitory Antibodies
CAS: 1418200-58-4
Last Update: 2025-05-21 16:50:25

Fazpilodemab

Category: Inhibitory Antibodies
CAS: 2517935-02-1
Last Update: 2025-05-21 16:50:25

Osemitamab

Category: Inhibitory Antibodies
CAS: 2460539-61-9
Last Update: 2025-05-21 16:50:25

Visugromab

Category: Inhibitory Antibodies
CAS: 2556646-63-8
Last Update: 2025-05-21 16:50:25

Vobramitamab

Category: Inhibitory Antibodies
CAS: 2490556-50-6
Last Update: 2025-05-21 16:50:25


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact